Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: Changes of aqueous vascular endothelial growth factor

American Journal of Ophthalmology

Volumn 156, Issue 2, 2013, Pages 343-348

  Lee, Mee Yon ^b   Lee, Won Ki ^a   Baek, Jiwon ^a   Kwon, Oh Woong ^c   Lee, Jin Hae ^a  

^a The Catholic University of Korea   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c NUNE Eye Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN;

AQUEOUS HUMOR; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; CHOROID; CHOROID DISEASES; COLORING AGENTS; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMMUNOASSAY; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PHOTOCHEMOTHERAPY; POLYPS; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84880573266     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.04.001     Document Type: Article

References (30)

1. R.M. Ahuja, P.E. Stanga, J.R. Vingerling, A.C. Reck, and A.C. Bird Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments Br J Ophthalmol 84 5 2000 479 484
2. M. Uyama, M. Wada, and Y. Nagai Polypoidal choroidal vasculopathy: natural history Am J Ophthalmol 133 5 2002 639 648
3. M. Matsuoka, N. Ogata, T. Otsuji, T. Nishimura, K. Takahashi, and M. Matsumura Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy Br J Ophthalmol 88 6 2004 809 815
4. H. Terasaki, Y. Miyake, T. Suzuki, M. Nakamura, and T. Nagasaka Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation Br J Ophthalmol 86 3 2002 321 327
5. H. Nakashizuka, M. Mitsumata, and S. Okisaka Clinicopathologic findings in polypoidal choroidal vasculopathy Invest Ophthalmol Vis Sci 49 11 2008 4729 4737
6. J.P. Tong, W.M. Chan, and D.T. Liu Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal vasculopathy and choroidal neovascularization Am J Ophthalmol 141 3 2006 456 462
7. S. Sasaki, D. Miyazaki, and K. Miyake Associations of IL-23 with polypoidal choroidal vasculopathy Invest Ophthalmol Vis Sci 53 7 2012 3424 3430
8. F. Gomi, M. Sawa, and H. Sakaguchi Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy Br J Ophthalmol 92 1 2008 70 73
9. C.K. Cheng, C.H. Peng, C.K. Chang, C.C. Hu, and L.J. Chen One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy Retina 31 5 2011 846 856
10. A. Koh, W.K. Lee, and L.J. Chen EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Retina 32 8 2012 1453 1464
11. W.M. Chan, D.S. Lam, and T.Y. Lai Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy vasculopathy: one-year results of a prospective case series Ophthalmology 111 8 2004 1576 1584
12. F. Gomi, M. Ohji, and K. Sayanagi One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients Ophthalmology 115 1 2008 141 146
13. E. Akaza, M. Yuzawa, and R. Mori Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy Jpn J Ophthalmol 55 1 2011 39 44
14. K.S. Kim, and W.K. Lee Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy Jpn J Ophthalmol 55 4 2011 370 377
15. M. Imasawa, Y. Sakurada, and H. Iijima Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy Jpn J Ophthalmol 55 3 2011 241 247
16. F. Ricci, A. Calabrese, F. Regine, F. Missiroli, and A.P. Ciardella Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy Retina 32 7 2012 1280 1288
17. A. Yamashita, F. Shiraga, C. Shiragami, Y. Shirakata, and A. Fujiwara Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 155 1 2013 96 102
18. T.Y. Lai, G.K. Lee, F.O. Luk, and D.S. Lam Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy Retina 31 8 2011 1581 1588
19. P. Ruamviboonsuk, M. Tadarati, S. Vanichvaranont, P. Hanutsaha, and N. Pokawattana Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study Br J Ophthalmol 94 8 2010 1045 1051
20. F. Gomi, M. Sawa, T. Wakabayashi, Y. Sasamoto, M. Suzuki, and M. Tsujikawa Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 150 1 2010 48 54
21. U. Schmidt-Erfurth, U. Schlötzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G.O. Naumann Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor Invest Ophthalmol Vis Sci 44 10 2003 4473 4480
22. O. Tatar, K. Shinoda, and A. Adam Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes Br J Ophthalmol 91 2 2007 166 173
23. O. Tatar, E. Kaiserling, and A. Adam Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes Arch Ophthalmol 124 6 2006 815 823
24. O. Tatar, A. Adam, and K. Shinoda Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy Am J Ophthalmol 142 1 2006 95 104
25. U. Schmidt-Erfurth, and S. Michels Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin Ophthalmology 110 7 2003 1306 1314
26. H.G. Blaauwgeers, G.M. Holtkamp, and H. Rutten Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation Am J Pathol 155 2 1999 421 428
27. M. Funk, D. Karl, and M. Georgopoulos Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab Ophthalmology 116 12 2009 2393 2399
28. J. Gaudreault, D. Fei, J. Rusit, P. Suboc, and V. Shiu Preclinical pharmacokinetics of ranibizumab(rhuFabV2) after a single intravitreal administration Invest Ophthalmol Vis Sci 46 2 2005 726 733
29. H. Noma, H. Funatsu, and M. Yamasaki Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion Eye 22 1 2008 42 48
30. S. Michels, F. Hansmann, W. Geitzenauer, and U. Schmidt-Erfurth Influence of treatment parameters on selectivity of verteporfin therapy Invest Ophthalmol Vis Sci 47 1 2006 371 376